Korean J Urol.  2012 Apr;53(4):229-233.

Renal Cell Carcinoma in Kidney Transplant Recipients and Dialysis Patients

• Lee HH
• Choi KH
• Yang SC
• Han WK

Abstract

PURPOSE
In a group of surgery patients diagnosed with renal cell cancer, those who underwent dialysis were compared with those who received a kidney transplant.
MATERIALS AND METHODS
The 43 subjects included in this study were patients who had been undergoing dialysis because of end-stage renal disease or had undergone kidney transplantation. The patients were diagnosed with renal cell carcinoma (RCC) during follow-up and underwent radical nephrectomy from May 1996 to December 2010. Their medical records were retrospectively analyzed as part of the study.
RESULTS
In the transplantation group, the renal replacement therapy period averaged 54 months, and the period from transplantation to RCC averaged 119 months (range, 0 to 264 months). In the dialysis group, RCC was observed after an average of 124 months (range, 2 to 228 months) of dialysis, and nephrectomy was then conducted. Acquired cystic kidney disease (ACKD) was found more frequently in the dialysis group, and it had a statistically relevant effect on the occurrence of RCC by comparison with the transplantation group (p<0.01).
CONCLUSIONS
Although the incidence rate of ACKD was significantly higher in the dialysis group among patients undergoing surgery for RCC, cancer was found even without ACKD development in some transplant recipients. Considering that the transplant recipients also underwent dialysis, an informative prospective study will be necessary to determine whether other immunosuppressive agents besides ACKD may function as a cancer risk factor.

Keyword

Cystic kidney disease; Dialysis; End stage renal disease; Kidney transplantation; Renal cell carcinoma

MeSH Terms

Carcinoma, Renal Cell
Dialysis
Follow-Up Studies
Humans
Immunosuppressive Agents
Incidence
Kidney
Kidney Diseases, Cystic
Kidney Failure, Chronic
Kidney Transplantation
Medical Records
Nephrectomy
Renal Replacement Therapy
Retrospective Studies
Risk Factors
Transplants
Immunosuppressive Agents

Reference

1. Motzer RJ, Bander NH, Nanus DM. Renal-cell carcinoma. N Engl J Med. 1996. 335:865–875.

2. Morath C, Mueller M, Goldschmidt H, Schwenger V, Opelz G, Zeier M. Malignancy in renal transplantation. J Am Soc Nephrol. 2004. 15:1582–1588.

3. Penn I. Cancers in renal transplant recipients. Adv Ren Replace Ther. 2000. 7:147–156.

4. Moudouni SM, Lakmichi A, Tligui M, Rafii A, Tchala K, Haab F, et al. Renal cell carcinoma of native kidney in renal transplant recipients. BJU Int. 2006. 98:298–302.

5. Matson MA, Cohen EP. Acquired cystic kidney disease: occurrence, prevalence, and renal cancers. Medicine (Baltimore). 1990. 69:217–226.

6. Ishikawa I, Hayama S, Morita K, Nakazawa T, Yokoyama H, Honda R, et al. Long-term natural history of acquired cystic disease of the kidney. Ther Apher Dial. 2010. 14:409–416.

7. Dunnill MS, Millard PR, Oliver D. Acquired cystic disease of the kidneys: a hazard of long-term intermittent maintenance haemodialysis. J Clin Pathol. 1977. 30:868–877.

8. Chandhoke PS, Torrence RJ, Clayman RV, Rothstein M. Acquired cystic disease of the kidney: a management dilemma. J Urol. 1992. 147:969–974.

9. Kojima Y, Takahara S, Miyake O, Nonomura N, Morimoto A, Mori H. Renal cell carcinoma in dialysis patients: a single center experience. Int J Urol. 2006. 13:1045–1048.

10. Ianhez LE, Lucon M, Nahas WC, Sabbaga E, Saldanha LB, Lucon AM, et al. Renal cell carcinoma in renal transplant patients. Urology. 2007. 69:462–464.

11. Pope JC, Koch MO, Bluth RF. Renal cell carcinoma in patients with end-stage renal disease: a comparison of clinical significance in patients receiving hemodialysis and those with renal transplants. Urology. 1994. 44:497–501.

12. Heinz-Peer G, Schoder M, Rand T, Mayer G, Mostbeck GH. Prevalence of acquired cystic kidney disease and tumors in native kidneys of renal transplant recipients: a prospective US study. Radiology. 1995. 195:667–671.